Jiangsu Osaikang injection with omeprazole sodium the first review

On January 5, the official website of the State Drug Administration showed that Jiangsu Osaikang injection with sodium omeprazole passed the consistent evaluation, which is the first manufacturer of this variety.
omeprazole is a pair of active spin-to-reflection mixture, belonging to the first generation of PPI drugs, with weak alkaline, specific combination of H-K-K-ATP enzyme, inhibit enzyme activity, thereby inhibiting the final link of gastric acid secretion.
clinical treatment is mainly used as an alternative therapy not applicable to oral therapy for the treatment of heterointestinal ulcers, stomach ulcers, refringer esopathy and Zollinger-Ellison syndrome.
is recommended for first-line medication in clinical guidelines.
sodium omeprazole for injection is the national base drug, Medicare Class B varieties.
there are currently 86 production enterprises in China.
M.A. Medical Cube IPM database shows that sodium omeprazole will have a national sales of 4 billion yuan in 2019, of which injections account for more than 95%.
by the Pharmaceutical Rubik's Cube PharmaGo database, in addition to Osaikang's first review, there are currently 20 enterprises including Stone Pharmaceutical Group, Yichang Renfu, Hunan Colum, including in the consistent evaluation declaration / same declaration stage.
sodium omeprazole for injection is the fifth consistent evaluation variety of Osaikang, and the same target drug injection with lansolazole and injection with sodium vitolazole have also passed the consistent evaluation.